Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)
Stopped Study discontinuation based on strategic sponsor decision; not driven by any safety concerns.
Conditions
- Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
- DRUG: Isatuximab SAR650984
Sponsor
Sanofi